GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ka Young | - |
dc.contributor.author | Shin, Ki Young | - |
dc.contributor.author | Chang, Keun-A | - |
dc.date.accessioned | 2023-05-23T08:40:50Z | - |
dc.date.available | 2023-05-23T08:40:50Z | - |
dc.date.created | 2023-05-23 | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 2073-4409 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87975 | - |
dc.description.abstract | Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring of Alzheimer's disease (AD). Although amyloid-beta peptide (A beta) and tau are primarily blood biomarkers, recent studies have identified other reliable candidates that can serve as measurable indicators of pathological conditions. One such candidate is the glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein that can be detected in blood samples. Increasing evidence suggests that blood GFAP levels can be used to detect early-stage AD. In this systematic review and meta-analysis, we aimed to evaluate GFAP in peripheral blood as a biomarker for AD and provide an overview of the evidence regarding its utility. Our analysis revealed that the GFAP level in the blood was higher in the A beta-positive group than in the negative groups, and in individuals with AD or mild cognitive impairment (MCI) compared to the healthy controls. Therefore, we believe that the clinical use of blood GFAP measurements has the potential to accelerate the diagnosis and improve the prognosis of AD. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | CELLS | - |
dc.title | GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000986213600001 | - |
dc.identifier.doi | 10.3390/cells12091309 | - |
dc.identifier.bibliographicCitation | CELLS, v.12, no.9 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85159185437 | - |
dc.citation.title | CELLS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 9 | - |
dc.contributor.affiliatedAuthor | Kim, Ka Young | - |
dc.contributor.affiliatedAuthor | Chang, Keun-A | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | cognitive impairment | - |
dc.subject.keywordAuthor | glial fibrillary acidic protein | - |
dc.subject.keywordAuthor | GFAP | - |
dc.subject.keywordAuthor | blood biomarker | - |
dc.subject.keywordPlus | FIBRILLARY ACIDIC PROTEIN | - |
dc.subject.keywordPlus | BLOOD-BASED BIOMARKERS | - |
dc.subject.keywordPlus | INTRACEREBRAL HEMORRHAGE | - |
dc.subject.keywordPlus | AMYLOID-BETA | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | ASTROCYTOSIS | - |
dc.subject.keywordPlus | BRAIN | - |
dc.subject.keywordPlus | PET | - |
dc.subject.keywordPlus | PATHOLOGY | - |
dc.subject.keywordPlus | ACCURACY | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.